Your browser doesn't support javascript.
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry.
Wei, Congwen; Wan, Luming; Yan, Qiulin; Wang, Xiaolin; Zhang, Jun; Yang, Xiaopan; Zhang, Yanhong; Fan, Chen; Li, Dongyu; Deng, Yongqiang; Sun, Jin; Gong, Jing; Yang, Xiaoli; Wang, Yufei; Wang, Xuejun; Li, Jianmin; Yang, Huan; Li, Huilong; Zhang, Zhe; Wang, Rong; Du, Peng; Zong, Yulong; Yin, Feng; Zhang, Wanchuan; Wang, Nan; Peng, Yumeng; Lin, Haotian; Feng, Jiangyue; Qin, Chengfeng; Chen, Wei; Gao, Qi; Zhang, Rui; Cao, Yuan; Zhong, Hui.
  • Wei C; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Wan L; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Yan Q; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Wang X; Institute of Physical Science and Information Technology, Anhui University, Hefei, China.
  • Zhang J; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Yang X; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Zhang Y; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Fan C; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Li D; Department of Basic Medical Sciences, The 960th Hospital of PLA, Jinan, China.
  • Deng Y; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Sun J; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing, China.
  • Gong J; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Yang X; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Wang Y; Institute of Physical Science and Information Technology, Anhui University, Hefei, China.
  • Wang X; Department of Clinical Laboratory, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
  • Li J; Department of Clinical Laboratory, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
  • Yang H; Beijing Institute of Radiation Medicine, AMMS, Beijing, China.
  • Li H; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Zhang Z; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Wang R; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Du P; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Zong Y; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Yin F; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Zhang W; Department of Laboratory Medicine, Taian City Central Hospital Branch, Taian, China.
  • Wang N; Department of Laboratory Medicine, Taian City Central Hospital Branch, Taian, China.
  • Peng Y; Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Lin H; Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Feng J; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Qin C; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Chen W; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Gao Q; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing, China.
  • Zhang R; Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China.
  • Cao Y; Beijing Hotgen Biotech Co., Ltd., Beijing, China.
  • Zhong H; Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China. zhangrui@cancerhosp-ln-cmu.com.
Nat Metab ; 2(12): 1391-1400, 2020 12.
Article in English | MEDLINE | ID: covidwho-947555
ABSTRACT
Responsible for the ongoing coronavirus disease 19 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through binding of the viral spike protein (SARS-2-S) to the cell-surface receptor angiotensin-converting enzyme 2 (ACE2). Here we show that the high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) facilitates ACE2-dependent entry of SARS-CoV-2. We find that the S1 subunit of SARS-2-S binds to cholesterol and possibly to HDL components to enhance viral uptake in vitro. SR-B1 expression facilitates SARS-CoV-2 entry into ACE2-expressing cells by augmenting virus attachment. Blockade of the cholesterol-binding site on SARS-2-S1 with a monoclonal antibody, or treatment of cultured cells with pharmacological SR-B1 antagonists, inhibits HDL-enhanced SARS-CoV-2 infection. We further show that SR-B1 is coexpressed with ACE2 in human pulmonary tissue and in several extrapulmonary tissues. Our findings reveal that SR-B1 acts as a host factor that promotes SARS-CoV-2 entry and may help explain viral tropism, identify a possible molecular connection between COVID-19 and lipoprotein metabolism, and highlight SR-B1 as a potential therapeutic target to interfere with SARS-CoV-2 infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Scavenger Receptors, Class B / Virus Internalization / Host-Pathogen Interactions / SARS-CoV-2 / COVID-19 / Lipoproteins, HDL Limits: Humans Language: English Journal: Nat Metab Year: 2020 Document Type: Article Affiliation country: S42255-020-00324-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Scavenger Receptors, Class B / Virus Internalization / Host-Pathogen Interactions / SARS-CoV-2 / COVID-19 / Lipoproteins, HDL Limits: Humans Language: English Journal: Nat Metab Year: 2020 Document Type: Article Affiliation country: S42255-020-00324-0